Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://evanse936yho0.wikiinside.com/user